Severity
Moderate
FDA Drug recall · Reported September 3, 2014
Customer complaints for failure to deliver the dose.
Alkermes, Inc. recalled VIVITROL (naltrexone for extended-release injectable suspension); 380 mg vial NDC 65757-… - a moderate-severity action.
VIVITROL (naltrexone for extended-release injectable suspension); 380 mg vial NDC 65757-… was recalled by Alkermes, Inc. in September 3, 2014. Reason: Customer complaints for failure to deliver the dose.. Check the official notice for the remedy. Verify recall #D-1556-2014 with the FDA Drug before acting.
The recall
Alkermes, Inc. issued this moderate-severity FDA Drug recall-Customer complaints for failure to deliver the dose..
Sourced from official FDA Drug enforcement records. Verify recall #D-1556-2014 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1556-2014) was formally reported on September 3, 2014, with the manufacturer initiating the action on March 4, 2014. It is classified under Moderate severity (Class II), with a current status of Terminated. Alkermes, Inc. is listed as the recalling firm, operating out of Waltham, MA. Federal records list the affected scope as 4,364 vials.
The documented reason for this recall is: Customer complaints for failure to deliver the dose. Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
4,364 vials
Related Recalls
6
5 from same agency
VIVITROL (naltrexone for extended-release injectable suspension); 380 mg vial NDC 65757-300-01; RX Only Manufactured and marketed by Alkermes, Inc., Waltham, MA 02451.
Customer complaints for failure to deliver the dose.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-1556-2014 |
| Date reported | September 3, 2014 |
| Date initiated | March 4, 2014 |
| Recalling firm | Alkermes, Inc. |
| Firm location | Waltham, MA |
| Affected scope | 4,364 vials |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported September 3, 2014. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.